Citi analyst Geoff Meacham raised the firm’s price target on Gilead (GILD) to $165 from $156 and keeps a Buy rating on the shares. The firm adjusted targets in the biopharma space as part of a Q1 preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead price target raised to $175 from $171 at Morgan Stanley
- MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
- Tempus AI announce strategic collaboration with Gilead
- Kymera Therapeutics announces Gilead option exercise to license KT-200
- Gilead price target raised to $155 from $152 at Truist